Scarica l'app Stockscreener
1.69
2.87%
-0.05
Precedente Chiudi:
$1.74
Aprire:
$1.66
Volume 24 ore:
82,191
Relative Volume:
0.35
Capitalizzazione di mercato:
$12.83M
Reddito:
Utile/perdita netta:
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
1 W Prestazione:
-5.59%
1M Prestazione:
-20.28%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$1.55
$1.96
Portata 52W:
$1.485
$4.1599
Cerenome, Inc. Common Stock Stock (CNSY) Company Profile
Nome
Cerenome, Inc. Common Stock
Settore
Industria
Telefono
-
Indirizzo
-
Compare CNSY vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNSY
Cerenome, Inc. Common Stock
|
1.69 | 12.83M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cerenome, Inc. Common Stock Stock (CNSY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-03 | Iniziato | Lake Street | Buy |
| 2025-09-03 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Iniziato | D. Boral Capital | Buy |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Cerenome, Inc. Common Stock Borsa (CNSY) Ultime notizie
New Strong Sell Stocks for October 15th - Zacks Investment Research
Form 4 Cerenome, Inc For: 1 October By Investing.com - Investing.com Canada
Form 4 Cerenome, Inc For: 1 October - Investing.com India
Form 4 Cerenome, Inc For: 1 October By Investing.com - Investing.com UK
After stock grant vesting, Cerenome (CNSY) director Kyle Guse holds 1,843 shares directly. - Stock Titan
Three stock grants vest, giving Cerenome (CNSY)'s CFO 2,985 common shares. - Stock Titan
After acquiring 921 shares, Cerenome (CNSY) director holds 1,843 shares directly. - Stock Titan
Three stock grants vest as Cerenome (CNSY) CEO Hedrick acquires 6,387, 8,066 and 1,986 shares. - Stock Titan
A director acquires 921 shares as Cerenome (CNSY) stock grants vest, bringing direct holdings to 1,843. - Stock Titan
A stock grant vests at Cerenome (CNSY). Director Hawkins acquires 921 shares and holds 2,450 common shares. - Stock Titan
Form 4 Cerenome, Inc For: 1 October By Investing.com - Investing.com South Africa
Cerenome, Inc. (CNSY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cerenome, Inc. (CNSY) stock price, news, quote and history - Yahoo Finance UK
Cerenome plans to discuss billing and access for its spinal-fluid diagnostic platform. - Stock Titan
ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Cerenome forecasts its cash will last into 2028 with new financing - Stock Titan
Cerenome, Inc. announced that it expects to receive $20 million in funding from 3i Fund - marketscreener.com
Cerenome Launches New Corporate Identity As Integrated CNS Oncology Company | News - Voice of Alexandria
CNSY | Cerenome, Inc. Common Stock Stock Data, Price & News - Quiver Quantitative
Cerenome Reports Second Quarter 2026 Financial Results and Business Update - The Manila Times
What is the current Price Target and Forecast for Cerenome, Inc. (CNSY) - Zacks Investment Research
Cerenome, Inc. Stock (CNSY)Quote Nasdaq - marketscreener.com
CNSY Forecast — Price Target — Prediction for 2027 - TradingView
Cerenome (Nasdaq:CNSY)주식 분석 - simplywall.st
Cerenome (Nasdaq:CNSY)Stock Analysis - Simply Wall Street
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
CNSYCerenome Inc Stock Price and Quote - Finviz
Plus Therapeutics, Inc. will Change its Ticker to CNSY from PSTV - marketscreener.com
Cerenome will combine CNS cancer diagnostics, treatments and AI Aug. 3 - Stock Titan
Cerenome Launches as an Integrated CNS Oncology Company - GlobeNewswire
Cerenome Launches as an Integrated CNS Oncology Company - Yahoo Finance
Plus Therapeutics' CNSide Tests Influenced Treatment Decisions in 90% of Cases - Stock Titan
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - finance.yahoo.com
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY - Investing.com
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding - GlobeNewswire
Plus Therapeutics Reports First Quarter 2026 Financial - GlobeNewswire
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Plus Therapeutics taps ex-Kiora executive to help push CNS cancer pipeline - Stock Titan
To keep its Nasdaq listing, Plus Therapeutics enacts 1-for-25 split - Stock Titan
Plus Therapeutics Announces Reverse Stock Split - GlobeNewswire
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Plus Therapeutics Reports 2025 Results, Business Progress - GlobeNewswire
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
LTRN Stock Price and Chart — NASDAQ:LTRN - tradingview.com
PLUS THERAPEUTICS (PSTV) Stock Price, News & Analysis - Stock Titan
EGRX Stock Price and Chart — OTC:EGRX - TradingView
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Cerenome, Inc. Common Stock Azioni (CNSY) Dati Finanziari
Non sono disponibili dati finanziari per Cerenome, Inc. Common Stock (CNSY). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Cerenome, Inc. Common Stock Azioni (CNSY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Guse Kyle | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
1,843 |
| Hawkins Richard J | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
2,450 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
2,985 |
0 |
12,926 |
| Clowes Howard | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
2,902 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
16,439 |
0 |
60,922 |
| ANDREWS RONALD ASBURY | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
1,843 |
| ANDREWS RONALD ASBURY | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| van Es-Johansson An | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| HEDRICK MARC H | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
0.00 |
16,439 |
0 |
44,483 |
| Clowes Howard | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
1,981 |
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):